These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 17109496)
1. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. Tonus C; Neupert G; Sellinger M World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496 [TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Caviglia GP; Cabianca L; Fagoonee S; Gili FM Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025 [TBL] [Abstract][Full Text] [Related]
3. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517 [TBL] [Abstract][Full Text] [Related]
4. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test. Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070 [TBL] [Abstract][Full Text] [Related]
5. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Koss K; Maxton D; Jankowski JA Colorectal Dis; 2008 Mar; 10(3):244-8. PubMed ID: 17784868 [TBL] [Abstract][Full Text] [Related]
7. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer. Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors. Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer. Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277 [TBL] [Abstract][Full Text] [Related]
10. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. Tonus C; Sellinger M; Koss K; Neupert G World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551 [TBL] [Abstract][Full Text] [Related]
11. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms. Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327 [TBL] [Abstract][Full Text] [Related]
12. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138 [TBL] [Abstract][Full Text] [Related]
13. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612 [TBL] [Abstract][Full Text] [Related]
14. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312 [TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer]. Li Y; Wang JJ Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720 [TBL] [Abstract][Full Text] [Related]
16. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127 [TBL] [Abstract][Full Text] [Related]
17. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma]. Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373 [TBL] [Abstract][Full Text] [Related]
18. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608 [TBL] [Abstract][Full Text] [Related]
19. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. Dollinger MM; Behl S; Fleig WE Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of different stool tests for the detection of cancer of the colon]. Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]